Senti Biosciences (SNTI) stock rocketed higher on Tuesday after the clinical-stage biotechnology company announced new data from its ongoing clinical trial of SENTI-202. This is a first-in-class CD33/FLT3 targeting, Logic Gated CAR NK cell therapy being studied in patients with relapsed or refractory Acute Myeloid Leukemia (AML). AML is a fast-growing cancer that targets the blood and bone marrow.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The data revealed by Senti Biosciences today show that 50% of patients at the recommended Phase 2 dose and 50% of all patients achieved an Overall Response Rate outcome. Additionally, 42% of patients at the recommended Phase 2 dose and 39% of all patients achieved a complete remission or a complete remission with partial hematologic recovery. The therapy has also been well tolerated, with no dose-limiting toxicities.
Kanya Rajangam, M.D., Ph.D., Chief Medical Officer at Senti Biosciences, said, “This clinical evidence, together with the receipt of recent RMAT and Orphan Drug Designations from the FDA, allows us to rapidly advance SENTI-202 into pivotal studies and to explore its potential in broader patient populations that may include newly diagnosed AML, pediatric AML, and myelodysplastic syndromes (MDS).”
Senti Biosciences Stock Movement Today
Senti Biosciences stock was up 22.59% in pre-market trading on Tuesday, following a 12.21% rally yesterday. The stock has fallen 31.91% year-to-date and 57.47% over the past 12 months.
With today’s news came heavy trading of SNTI stock, as some 39 million shares changed hands. For comparison, the stock’s three-month daily average trading volume is about 260,000 units.
Is Senti Biosciences Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Senti Biosciences is Strong Buy, based on three Buy ratings over the past three months. With that comes an average SNTI stock price target of $10, representing a potential 318.41% upside for the shares.
